CUMBERLAND PHARMACEUTICALS IN	1 C
Form 8-K	
July 10, 2017	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

July 10,

2017 (July

10, 2017)

Cumberland Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

(2.1400 Hamo of regionality as specified in its charter)

Tennessee 001-33637 62-1765329

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

37203

2525 West End Avenue, Suite 950, Nashville,

Tennessee

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (615) 255-0068

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On July 10, 2017, Clinigen Group plc and Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the FDA approval of Totect® (dexrazoxane hydrochloride) in the U.S. A copy of the press release is furnished as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

July 10, 2017 By: Michael Bonner

Name: Michael Bonner Title: Chief Financial Officer

Exhibit Index

Exhibit No. Description

Press release dated July 10, 2017